EU industry pools energies in bid to shape safe sourcing regulations
This article was originally published in Clinica
Executive Summary
Medical device companies operating in the EU have a number of "serious concerns" about two pieces of impending EU legislation that are intended to shape the future regulation of human tissue engineered products. The area is a complex, and moreover is one that could be hijacked by a misconceived ethical lobby. The task at hand is for industry therefore to proactively educate the decision-makers and opinion-formers, delegates heard at the recent Management Forum conference on Human Tissue Products, in London on November 19.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.